Cargando…

Exenatide: A New Promising Antidiabetic Agent

Exenatide is a unique agent which can effectively control blood glucose levels in type 2 diabetes mellitus without producing dangerous adverse effects. In addition, it can lower body weight which is very essential for the treatment of obese type 2 diabetes mellitus patients. Since it can delay the d...

Descripción completa

Detalles Bibliográficos
Autor principal:	Chakraborti, C. K.
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2010
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883206/ https://www.ncbi.nlm.nih.gov/pubmed/20582183 http://dx.doi.org/10.4103/0250-474X.62228

Ejemplares similares

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
por: Tatarkiewicz, K, et al.
Publicado: (2014)

Gliptins: A New Class of Oral Antidiabetic Agents
por: Seshadri, K. G., et al.
Publicado: (2009)

Vitamin D as a promising anticancer agent
por: Chakraborti, Chandra Kanti
Publicado: (2011)

Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke
por: Ahn, Chang Ho, et al.
Publicado: (2019)

Honey - A Novel Antidiabetic Agent
por: Erejuwa, Omotayo O., et al.
Publicado: (2012)

Long-acting preparations of exenatide
por: Cai, Yunpeng, et al.
Publicado: (2013)

The effects of antidiabetic agents on heart failure
por: Wijnen, M., et al.
Publicado: (2021)

In the Search of Glycoside-Based Molecules as Antidiabetic Agents
por: Pałasz, Aleksandra, et al.
Publicado: (2019)

The Anti-Inflammatory Effect of Novel Antidiabetic Agents
por: Theofilis, Panagiotis, et al.
Publicado: (2022)

Gnidia glauca- and Plumbago zeylanica-Mediated Synthesis of Novel Copper Nanoparticles as Promising Antidiabetic Agents
por: Jamdade, Dhiraj A., et al.
Publicado: (2019)

Role of red grape polyphenols as antidiabetic agents
por: Pandey, Kanti Bhooshan, et al.
Publicado: (2014)

Exenatide Is an Effective Antihyperglycaemic Agent in a Mouse Model of Wolfram Syndrome 1
por: Sedman, Tuuli, et al.
Publicado: (2016)

Exenatide once weekly: clinical outcomes and patient satisfaction
por: Jose, Biju, et al.
Publicado: (2010)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece
por: Tzanetakos, Charalampos, et al.
Publicado: (2014)

Antidiabetic Agents for Treatment of Parkinson’s Disease: A Meta-Analysis
por: Wang, Shu-Yi, et al.
Publicado: (2020)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018)

Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes
por: Zeng, Zhiwei, et al.
Publicado: (2020)

Promising Antidiabetic and Antimicrobial Agents Based on Fused Pyrimidine Derivatives: Molecular Modeling and Biological Evaluation with Histopathological Effect
por: Bassyouni, Fatma, et al.
Publicado: (2021)

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

New therapeutic strategy for Alzheimer's disease using antidiabetes agents
por: Yokono, Koichi
Publicado: (2013)

Anacardium occidentale Bark as an Antidiabetic Agent
por: Encarnação, Sofia, et al.
Publicado: (2022)

Exenatide Use in the Management of Type 2 Diabetes Mellitus
por: Kyriacou, Angelos, et al.
Publicado: (2010)

Cannabinoids: New Promising Agents in the Treatment of Neurological Diseases
por: Giacoppo, Sabrina, et al.
Publicado: (2014)

AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
por: Lu, Qingguo, et al.
Publicado: (2019)

Potential of Lichen Compounds as Antidiabetic Agents with Antioxidative Properties: A Review
por: Thadhani, Vinitha M., et al.
Publicado: (2017)

Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents
por: Vekic, Jelena, et al.
Publicado: (2021)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

Anthocyanins as Antidiabetic Agents—In Vitro and In Silico Approaches of Preventive and Therapeutic Effects
por: Oliveira, Hélder, et al.
Publicado: (2020)

Pharmacogenetics of new classes of antidiabetic drugs
por: Kadrić, Selma Imamović, et al.
Publicado: (2021)

Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment
por: Gangopadhyay, Kalyan Kumar, et al.
Publicado: (2017)

Application of Artificial Intelligence in Discovery and Development of Anticancer and Antidiabetic Therapeutic Agents
por: Alqahtani, Amal
Publicado: (2022)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

The Impact of Antidiabetic Agents on Sarcopenia in Type 2 Diabetes: A Literature Review
por: Wu, Chen-Ning, et al.
Publicado: (2020)

A review of exenatide as adjunctive therapy in patients with type 2 diabetes
por: Robles, Gisela I, et al.
Publicado: (2009)

Exenatide Once Weekly for Management of Type 2 Diabetes: A Review
por: Inaishi, Jun, et al.
Publicado: (2022)

SGLT inhibitors as antidiabetic agents: a comprehensive review
por: Kshirsagar, Rahul P., et al.
Publicado: (2020)

Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease
por: Lin, Wei-Ren, et al.
Publicado: (2023)

Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents
por: Mathur, Vishal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a2j3sn8rdl6q3oe971jecrtrkv